@MarkChangDO

Hem/Onc fellow at Atrium Health Levine Cancer Institute

 Charlotte, NC
Joined September 2018
  • Tweets449
  • Following177
  • Followers88
15Media
Mark Chang, DO retweeted
ASCO
@ASCOAug 6
🎙 @montypal of @cityofhope and @rachnatshroff of @UAZCancer discuss compelling data on GLP-1 RAs in GI cancers on the latest episode of the #ASCODailyNews Podcast: bit.ly/4w7JzUf
7
8
2
28
5,379
Mark Chang, DO retweeted
ASCO
@ASCOJul 21
🎉 #ASCOAdvocacy applauds @WaysandMeansGOP & @HouseCommerce for passing the #SeniorsAct: bit.ly/4yO2Dtw #FixPriorAuth
15
2
24
4,982
Mark Chang, DO retweeted
Giampaolo Bianchini
@BianchiniGPJun 2
🔥 More is not always the best REDUCE trial demonstrated that every 12 weeks denosumab is not inferior to standard every 4 weeks ✅ Non inferior efficacy ✅ Improved safety profile ✅ Reduce cost I love this type of trials! Congratulations to all investigators
4
32
7
77
25,741
Mark Chang, DO retweeted
ASCO
@ASCOJun 2
#ASCO26 truly embodied the theme of translating science into global patient outcomes. We are grateful to the ~46,000 attendees, all working tirelessly to conquer cancer together! A heartfelt thanks to all. 💗 We can’t wait to see you next year at #ASCO27!
65
43
11
142
33,340
Our @MOASC_Office & @ANCO_News joint luncheon was a highlight of my #ASCO26 meeting. Was a chance to reconvene with my extended @cityofhope team past & present (@PauloBergerot @crisbergerot @arafflemd @MarkChangDO @SalvadorjcMD @RWinayak @AlexisLeVee @DaniCastilloMD @irenekangmd) & interact with international leaders @VanitaNoronha (leading the TMC1 study that garnered so much attention at this meeting) & @yao_zhu_sh (now collaborating with @mzugman from @hosp_einstein!). Follow @MOASC_Office & go to moasc.org to learn more about our new programs including the MOASC YIA & the NextGen Scholars Program!
MOASC
@MOASC_OfficeMay 31
Insightful remarks from MOASC and ANCO leadership @montypal and @DasMillie11 at #ASCO26, highlighting exciting upcoming initiatives like YIA and NextGen. The future is bright! 🌟 @ASCO @MOASC_Office @ANCO_News
1
15
36
3,587
Mark Chang, DO retweeted
Brian Rini, MD@brian_riniJun 1
Does CTLA-4 inhibition benefit RCC patients?
1
18
2
30
6,392
Mark Chang, DO retweeted
Geraldine Carroll@GCarroll147Jun 1
🎙️@montypal unpacks highly anticipated data from Day 4 of #ASCO26 on the latest episode of the #ASCODailyNews Podcast! 🧬 EMERALD-3 Trial in #HCC 🧬 ALCHEMIST Trial in #NSCLC 🧬 ECOG 6174 (STAMP) in #MerkelCell Carcinoma 🎧Listen now: dailynews.ascopubs.org/do/po… @ASCO @cityofhope

Podcast: Day 4: Top Takeaways From ASCO26

Dr. Monty Pal shares highlights from Day 4 of the 2026 ASCO Annual Meeting, including a much-anticipated study in hepatocellular carcinoma, new data in non–small cell lung cancer, and a key update in...

dailynews.ascopubs.org
2
5
296
Mark Chang, DO retweeted
ASCO
@ASCOJun 2
CMS has released its Interim Final Rule regarding Medicaid work requirements. To ensure continuous access to care, #ASCOAdvocacy is closely monitoring how these state-level reporting structures will impact patients with cancer & their caregivers: bit.ly/4dRP56s
1
3
10
1,950
Mark Chang, DO retweeted
Steve Lee@steveleeycJun 1
The role of the @AmerMedicalAssn is to take the genius of this place #asco26 to America - and advocate for access to these advances - @PresAmerMed, and #BrainCancer survivor Bobby Mukkamala. @ASCO @AshleySumrallMD – at Chicago, IL
1
1
2
9
1,816
Mark Chang, DO retweeted
Steve Lee@steveleeycJun 1
Replying to @steveleeyc @PresAmerMed
Practice viability faces challenges. Compared to giving office staff routine raises to keep pace with cost of living, "The way we feel about our employees is not how Congress feels about our physicians" #medicare #asco26 – at Chicago, IL
1
1
2
211
Mark Chang, DO retweeted
Steve Lee@steveleeycJun 1
His insurance approved vorasidenib for his Gr2 astrocytoma (#asco24 plenary!), but for only 2 weeks at a time, causing concern for missed drug, limited travel, and time toxicity of kludgy lab draws. #asco26 – at Chicago, IL
1
1
3
203
My fav session D4 of #ASCO2026. @PresAmerMed shared his struggle after being diagnosed with grade 2 astrocytoma. I took this selfie in 2024 prior to his AMA pres and brain cancer dx. His story exemplifies what many of our cancer pts also experience in our healthcare system. – at Chicago, IL
Steve Lee@steveleeycJun 1
The role of the @AmerMedicalAssn is to take the genius of this place #asco26 to America - and advocate for access to these advances - @PresAmerMed, and #BrainCancer survivor Bobby Mukkamala. @ASCO @AshleySumrallMD
1
2
4
843
Mark Chang, DO retweeted
Steve Lee@steveleeycJun 1
The @PresAmerMed was quoted $50k copay for vorasidenib by BC/BS; needed 14 hours of calls from his family for copay cards; was offered a financial assistance program! #asco26 – at Chicago, IL
1
2
3
310
Proud of @charlesbnguyen @cityofhope who just gave a phenomenal overview of #papillary #kidneycancer therapy at #ASCO26. He has been building an impressive portfolio of studies at @cityofhopeoc in GU cancers! Great perspectives shown today including data from @DrChoueiri, @tompowles1, @crisuarez08, @scocmem, @AlbigesL, @mzugman, @theNCI & from this very meeting from @DrDarrenFeldman for cabo/nivo.
1
23
2
55
2,786
Terrific job by my friend & @AtriumHealthWFB colleague, @JohnMSalsmanPhD on living well for #AYACSM #asco26 @WakeCancer
Fumiko Ladd Chino, MD, FASCO@fumikochinoJun 1
Dr @JohnMSalsmanPhD #ASCO26 on a RCT #AYACSM to improve how young adult cancer survivors "live well". This #survonc study was a 5 week self-guided digital health intervention with affective, behavioral, & cognitive skills. Interesting findings w/o clear intervention benefit.
1
3
337
For @ASCO aficionados, there have been questions as to how many standing ovations we have seen. The first I saw was adjuvant Herceptin in 2005. ChatGPT generated the list below for me when prompted for ASCO presentations with standing ovations.
Adam Feuerstein ✡️
@adamfeuersteinMay 31
Incredible #ASCO26 moment. Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD
7
40
5
151
26,215
Mark Chang, DO retweeted
City of Hope@cityofhopeJun 1
Dr. Pashtoon Kasi (@pashtoonkasi), medical director of GI oncology at @cityofhope Orange County, breaks down the latest advances in RAS-targeted therapies at #ASCO26 and what they mean for patients across pancreatic, colorectal, and lung cancer.
1
4
15
937
Mark Chang, DO retweeted
Steve Lee@steveleeycJun 1
Replying to @steveleeyc @PresAmerMed
New #medicaid work requirements delay workup of pre-diagnosis cancer patients, and is focus of @ASCO advocacy - @AshleySumrallMD, delegate from ASCO to #amahod asco.org/news-initiatives/po… – at Chicago, IL
2
2
261
Mark Chang, DO retweeted
ASCO
@ASCOMay 31
The final study presented at #ASCO26 Plenary: RASolute-302 results show daraxonrasib meeting all primary and key secondary endpoints, demonstrating significant and clinically meaningful improvements in OS, PFS, and ORR in metastatic #PDAC: bit.ly/49r62n1 #ASCODailyNews
12
3
29
2,928
Mark Chang, DO retweeted
ASCO
@ASCOMay 31
Major news from #ASCO26: A multi-selective RAS(ON) inhibitor nearly doubles survival time in people with metastatic pancreatic cancer. “This is absolutely practice-changing” says @ShrutiPatelMD in this Science in Seconds. #pancan Read the abstract: bit.ly/4dChEWM
27
2
46
4,726
Load more